Visit us at the NASPGHAN, Chicago, 16.-19.10. 2019

Living the impossible

More info

Visit us at the World of Microbiome, Milan, 31.10.-02.11. 2019

Living the impossible

More info

Visit us at the CPhI, Frankfurt, 05.-07.11.2019

Living the impossible

More info

Living the impossible

More info

Jennewein Biotechnologie manufactures rare functional sugars for a wide range of applications, including nutritional, pharmaceutical and cosmetic products.

We are world leaders in the manufacture of rare monosaccharides and complex oligosaccharides.

Over the last 10 years, our focus on research and development has expanded to include industrial manufacturing of saccharides. Jennewein Biotechnologie is a company active in the field of industrial biotechnology with a strong scientific foundation.

In all our activities, our ambition is to contribute to the health and wellbeing of consumers through our products.

NEWS

12.09.2019

Administrative Law Judge issues ruling in patent dispute 2′-FL production and beta-galactosidase activity

On September 09, 2019, Administrative Law Judge Cameron Elliot of the US International Trade Commission issued an Initial Determination finding that one of the bacterial strains used by Jennewein Biotechnologie to make 2’-fucosyllactose (2’-FL) infringes a patent owned by Glycosyn LLC.In the ITC Investigation, Complainant Glycosyn initially asserted two separate patents and a total of 68 patent claims. After factual discovery, Glycosyn withdrew one of the patents in its entirety and limited the other patent to 14 patent claims. Jennewein intends to appeal the ALJ’s Initial Determination, which is subject to review by the entire Commission. According to President and CEO Stefan Jennewein, “We are disappointed in the ALJ’s Initial Determination but continue to firmly believe that our process does not infringe any of Glycosyn’s patent claims. We intend to appealing the decision to the entire Commission.” Jennewein has already made arrangements for the use of alternative strains lacking inducible beta-galactosidase activity to ensure that it will be able to continue to provide 2’-FL to its customers in the United States without any interruption. Says Mr. Jennewein,“Our company was the first to market 2’-FL in the United States and the first to obtain GRAS approval from the FDA, and we will continue to lead the way in bringing new and innovative human milk oligosaccharide products such as 2’-FL to the market for use in human infant formula and other products in the U.S. and…

read more

05.02.2019

Jennewein Biotechnologie and Yili Group join forces in China for microbiome research and human milk oligosaccharides for the largest baby food market

read more